Last reviewed · How we verify
Pioglitazone Plus dapaglifliozin
Pioglitazone is a thiazolidinedione that activates PPAR-γ, increasing insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys.
Pioglitazone is a thiazolidinedione that activates PPAR-γ, increasing insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys. Used for Type 2 diabetes, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
At a glance
| Generic name | Pioglitazone Plus dapaglifliozin |
|---|---|
| Sponsor | Hamad Medical Corporation |
| Drug class | SGLT2 inhibitor and thiazolidinedione |
| Target | PPAR-γ and SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Pioglitazone works by binding to PPAR-γ receptors in the nucleus, leading to increased expression of genes involved in glucose metabolism and insulin sensitivity. Dapagliflozin, on the other hand, inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.
Approved indications
- Type 2 diabetes
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Common side effects
- Weight gain
- Edema
- Hypoglycemia
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone Plus dapaglifliozin CI brief — competitive landscape report
- Pioglitazone Plus dapaglifliozin updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI